217 related articles for article (PubMed ID: 14659973)
1. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Kobayashi S; Ikeda K; Miyata K
Life Sci; 2004 Jan; 74(7):843-53. PubMed ID: 14659973
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
[TBL] [Abstract][Full Text] [Related]
4. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model.
Naruganahalli KS; Sinha S; Hegde LG; Meru AV; Chugh A; Kumar N; Gupta JB; Ray A
Eur J Pharmacol; 2007 Oct; 572(2-3):207-12. PubMed ID: 17610864
[TBL] [Abstract][Full Text] [Related]
6. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
Ito Y; Oyunzul L; Yoshida A; Fujino T; Noguchi Y; Yuyama H; Ohtake A; Suzuki M; Sasamata M; Matsui M; Yamada S
Eur J Pharmacol; 2009 Aug; 615(1-3):201-6. PubMed ID: 19446545
[TBL] [Abstract][Full Text] [Related]
7. Tolterodine--a new bladder-selective antimuscarinic agent.
Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of tolterodine on human isolated urinary bladder.
Yono M; Yoshida M; Wada Y; Kikukawa H; Takahashi W; Inadome A; Seshita H; Ueda S
Eur J Pharmacol; 1999 Mar; 368(2-3):223-30. PubMed ID: 10193658
[TBL] [Abstract][Full Text] [Related]
9. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats.
Suzuki M; Ohtake A; Yoshino T; Yuyama H; Hayashi A; Ukai M; Okutsu H; Noguchi Y; Sato S; Sasamata M
Eur J Pharmacol; 2005 Apr; 512(1):61-6. PubMed ID: 15814091
[TBL] [Abstract][Full Text] [Related]
10. Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
Moro C; Uchiyama J; Chess-Williams R
Urology; 2011 Dec; 78(6):1442.e9-15. PubMed ID: 22001099
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
Gillberg PG; Sundquist S; Nilvebrant L
Eur J Pharmacol; 1998 May; 349(2-3):285-92. PubMed ID: 9671109
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.
Salcedo C; Davalillo S; Cabellos J; Lagunas C; Balsa D; Pérez-Del-Pulgar S; Ballarín M; Fernández A
Br J Pharmacol; 2009 Mar; 156(5):807-17. PubMed ID: 19222482
[TBL] [Abstract][Full Text] [Related]
14. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
[TBL] [Abstract][Full Text] [Related]
15. The emergence of new drugs for overactive bladder.
McCrery RJ; Smith PP; Appell RA
Expert Opin Emerg Drugs; 2006 Mar; 11(1):125-36. PubMed ID: 16503831
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic management of overactive bladder.
Lam S; Hilas O
Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
[TBL] [Abstract][Full Text] [Related]
17. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological effects of solifenacin on human isolated urinary bladder.
Masunaga K; Yoshida M; Inadome A; Murakami S; Sugiyama Y; Satoji Y; Maeda Y; Ueda S
Pharmacology; 2008; 82(1):43-52. PubMed ID: 18434763
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
Oki T; Sato S; Miyata K; Yamada S
Br J Pharmacol; 2005 May; 145(2):219-27. PubMed ID: 15753946
[TBL] [Abstract][Full Text] [Related]
20. Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers.
Chapple CR; Nilvebrant L
Drugs R D; 2002; 3(2):75-81. PubMed ID: 12001821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
